Compounds > marimastat
Page last updated: 2024-09-03

marimastat and n-((2s)-2-mercapto-1-oxo-4-(3,4,4- trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-l-leucyl-n,3- dimethyl-l-valinamide

marimastat has been researched along with n-((2s)-2-mercapto-1-oxo-4-(3,4,4- trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-l-leucyl-n,3- dimethyl-l-valinamide in 3 studies

Compound Research Comparison

Studies
(marimastat)		Trials
(marimastat)		Recent Studies (post-2010)
(marimastat)		Studies
(n-((2s)-2-mercapto-1-oxo-4-(3,4,4- trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-l-leucyl-n,3- dimethyl-l-valinamide)		Trials
(n-((2s)-2-mercapto-1-oxo-4-(3,4,4- trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-l-leucyl-n,3- dimethyl-l-valinamide)		Recent Studies (post-2010) (n-((2s)-2-mercapto-1-oxo-4-(3,4,4- trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-l-leucyl-n,3- dimethyl-l-valinamide)
21528531570

Protein Interaction Comparison

ProteinTaxonomymarimastat (IC50)n-((2s)-2-mercapto-1-oxo-4-(3,4,4- trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-l-leucyl-n,3- dimethyl-l-valinamide (IC50)
Interstitial collagenaseHomo sapiens (human)0.025
72 kDa type IV collagenaseHomo sapiens (human)0.041
Stromelysin-1Homo sapiens (human)0.157
Matrix metalloproteinase-9Homo sapiens (human)0.025

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Albert, DH; Bouska, JJ; Curtin, ML; Dai, Y; Davidsen, SK; Elmore, IN; Florjancic, AS; Garland, RB; Goodfellow, CL; Guo, Y; Heyman, HR; Holms, JH; Marcotte, PA; Michaelides, MR; Morgan, DW; Stacey, JR; Steinman, DH; Tapang, P; Wada, CK1
Eckhardt, SG; Hidalgo, M1
Didziapetriene, J; Kadziauskas, J; Stanciūte, D1

Reviews

2 review(s) available for marimastat and n-((2s)-2-mercapto-1-oxo-4-(3,4,4- trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-l-leucyl-n,3- dimethyl-l-valinamide

ArticleYear
Development of matrix metalloproteinase inhibitors in cancer therapy.
    Journal of the National Cancer Institute, 2001, Feb-07, Volume: 93, Issue:3

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Biphenyl Compounds; Clinical Trials as Topic; Drugs, Investigational; Enzyme Inhibitors; Humans; Hydroxamic Acids; Imidazoles; Matrix Metalloproteinase Inhibitors; Neoplasms; Organic Chemicals; Phenylalanine; Phenylbutyrates; Protease Inhibitors; Pyrazines; Sulfonamides; Tetracycline; Tetracyclines; Thiophenes

2001
[Expression of matrix metalloproteinases in patients with malignant tumors].
    Medicina (Kaunas, Lithuania), 2004, Volume: 40, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Clinical Trials as Topic; Diphosphonates; Disease Progression; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Humans; Hydroxamic Acids; Imidazoles; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasms; Organic Chemicals; Phenylalanine; Phenylbutyrates; Prognosis; Protease Inhibitors; Thiophenes; Time Factors; Tissue Inhibitor of Metalloproteinases

2004

Other Studies

1 other study(ies) available for marimastat and n-((2s)-2-mercapto-1-oxo-4-(3,4,4- trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-l-leucyl-n,3- dimethyl-l-valinamide

ArticleYear
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
    Journal of medicinal chemistry, 2002, Jan-03, Volume: 45, Issue:1

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Cell Line; Formamides; Hydroxylamines; Macaca fascicularis; Matrix Metalloproteinase Inhibitors; Metalloendopeptidases; Mice; Protease Inhibitors; Structure-Activity Relationship; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays

2002